Suboxone Sublingual Film

DRUG3 trials

Sponsors

Indivior Inc.

Conditions

Opioid DependenceOpioid Use DisorderOpioid-related Disorders

Phase 1

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

CompletedNCT02559973

Indivior Inc.Opioid Use Disorder

Start: 2015-09-30End: 2016-03-31Updated: 2017-01-31

Phase 3

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

CompletedNCT02510014

Indivior Inc.Opioid-related Disorders, Opioid Use Disorder

Start: 2015-07-27End: 2017-01-31Updated: 2018-03-29

Phase 4

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

CompletedNCT02038790

Indivior Inc.Opioid Dependence

Start: 2013-11-30End: 2013-11-30Updated: 2017-03-21

Related Papers

Treatment and recovery from opioid use disorder: The role of pain severity in individuals with moderate to severe pain.

2025-09-25

18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.

2023-08-306 citations

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings

Journal of Addiction Medicine2022-09-1612 citations

Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.

2022-03-0910 citations

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

Journal of Addiction Medicine2020-03-1350 citations